Status:
UNKNOWN
Immunoassay and Regulation of Traditional Chinese Medicine on Cancer Patients
Lead Sponsor:
China Medical University Hospital
Conditions:
Breast Cancer
Colorectal Cancer
Eligibility:
All Genders
20+ years
Phase:
NA
Brief Summary
The immune system is our body's defense mechanism, which helps us to resist foreign pathogens and cancer cells in the body. However, if the immune system is too weak, too strong, or unbalanced, it wil...
Detailed Description
Traditional Chinese medicine (TCM) and dendritic cells (DCs) activation/maturation One of the important approaches to successful cancer immunotherapy is generation of specific T cell responses by dend...
Eligibility Criteria
Inclusion
- Patients diagnosed with ovarian cancer and endometrial cancer (cancer patients treated with chemotherapy, radiotherapy, and surgery) can be included.
- Breast cancer: Diagnosed by pathological diagnosis of biopsy, without chemotherapy or radiotherapy.
- Colorectal cancer: Diagnosed by pathological diagnosis of slices, without chemotherapy or radiotherapy.
Exclusion
- Pregnant women
- Minors under the age of 20.
- Those who are currently using traditional Chinese medicine
Key Trial Info
Start Date :
May 18 2020
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
July 31 2023
Estimated Enrollment :
300 Patients enrolled
Trial Details
Trial ID
NCT04438564
Start Date
May 18 2020
End Date
July 31 2023
Last Update
February 8 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
China Medical University Hospital
Taichung, Taiwan